Commentary|Podcasts|January 29, 2026

Pharma Pulse: AI’s $120M Cardiometabolic Play

In today’s Pharma Pulse, the AAP defies federal vaccine cuts, Morris & Dickson scales its specialty footprint, and Insilico Medicine targets cardiometabolic health with a new partnership.

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

  • First, the American Academy of Pediatrics has released their own 2026 vaccine schedule in direct response to the recent HHS overhaul. While federal guidelines moved six routine vaccines to shared decision-making, the AAP is re-endorsing all 18 immunizations for US children.
  • In supply chain news, Morris & Dickson has officially acquired Prodigy Health. This significantly boosts the distributor’s reach into high-cost plasma-derived therapies and specialty care settings.
  • Lastly, Insilico Medicine has inked a $120 million deal with Qilu Pharmaceuticals. The company will be using Insilico’s Pharma.AI platform to design novel small molecules, aiming to slash discovery timelines for cardiometabolic diseases.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.


Related to this article

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | © Tada Images - stock.adobe.com 521699065
In this week’s Pharma Pulse, the FDA launches a program that lets companies share its approval packages with foreign regulators, UPS agrees to acquire Australia and New Zealand health care courier Smartways Logistics and Cognizant introduces an AI-enabled patient hub offering.
CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.